3 August 2016

Holding(s) in Company

RNS Number : 1066G
Verona Pharma PLC
03 August 2016
 

 

 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

 

 

VERONA PHARMA PLC

2 Reason for the notification (please tick the appropriate box or boxes):

 

An acquisition or disposal of voting rights

·

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

Other (please specify) :

 

 

3. Full name of person(s) subject to the notification obligation: iii

 

ARIX BIOSCIENCE HOLDINGS LTD &

WALES LIFE SCIENCES INVESTMENT FUND LP 'AFFILIATED' ENTITIES

 

 

4. Full name of shareholder(s)

(if different from 3.):iv

5. Date of the transaction and date on

which the threshold is crossed or reached: v

 

28 JULY 2016

 

6. Date on which issuer notified:

 

29 JULY 2016

 

7. Threshold(s) that is/are crossed or reached: vi, vii

 

10.6%

 

 

 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of

shares

 

if possible using the ISIN CODE

Situation previous to the triggering

transaction

Resulting situation after the triggering transaction

Number

of

Shares

Number

of

Voting

Rights

Number

of shares

Number of voting

rights

% of  voting rights x

Direct

Direct xi

Indirect  xr r

Direct

Indirect

 

ORDINARY

 

 

207 ,500,000

 

 

207,500,000

 

 

272,017,620

 

 

272,017,620

10.6%

 

 

B: Qualifying Financial Instruments

 

Resulting situation after the triggering transaction

Type of financial

instrument

Exercise/

Conversion Period xrv

Number of voting

rights that may be acquired if the instrument is exercised! converted.

%of voting

rights

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

XV, XV i

 

Resulting situation after the triggering transaction

Type of financial

instrument

Exercise

price

Expiration date XV II

Exercise/

Conversion period xviii

Number of voting rights

instrument refers to

%of voting rights xix,

XX

 

Nominal

 

Delta

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

272,017,620

 

10.6%

 

 

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

 

 

Wales Life Sciences Investment Fund LP previously held 20.55%, it now holds 8.1% as stand alone entity.

Arix Bioscience Holdings Ltd previously held 0%, it now holds 2.5% as a stand-alone entity following the new share issue.

Combined holding 10.6%

 

 

 

 

 

 

Proxy Voting:

 

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will cease to hold:

 

12. Date on which proxy holder will cease to hold voting  rights:

 

 

 

 

13. Additional information:

 

14. Contact name:

 

15. Contact telephone  number:

 

 

 

 

 

Note: Annex should only be submitted to the FCA not the issuer

 

Annex:  Notification of major interests  in shares xx ll

 

 

 

 

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

Arix Bioscience Holdings Ltd

Wales Life Sciences Investment Fund LP

Contact address

(registered office for legal entities)

 

20 Berkeley Square London W1J 6EQ

Phone number & email

 

020-7290-1050

Other useful information

(at least legal representative for legal persons)

 

 

 

8: Identity of the notifier, if applicable

Full name

 

James Rawlingson

Contact address

 

20 Berkeley Square London W1J 6EQ

Phone number & email

 

020-7290-1050

lnfo@arixbioscience .com

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

 

C: Additional information

 

 

 

 

 

 

 

 

For notes on how to complete form TR-1 please see the FCA website.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUGUAARUPQUMW

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us